Nov 12
Earnings call
Q3 2024 earnings call
PIII · P3 Health Partners Inc. · Documents
$2.70
-0.05 (-1.82%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q are issued.”View the 10-Q filed Nov 9, 2026
Market Cap
$19.61M
Shares
7.26M
Volume · Nov 13
29.47K
Avg daily vol (3M)
30.21K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2024
Nov 12
Current report
8-K
Financial results
Nov 12
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $362.12M
▲ 25.6%
Net loss $46.51M
Diluted EPS -$0.31
Aug 29
Current report
8-K
Director or officer change, or executive pay
Aug 7
Earnings call
Q2 2024 earnings call
Aug 7
Current report
8-K
Financial results
Aug 7
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $379.16M
▲ 15.2%
Net loss $12.02M
Diluted EPS -$0.15
Jun 18
Registration statement
S-3
Registration statement
Jun 7
Current report
8-K
Events of Jun 6
Shareholder vote results
May 24
Current report
8-K
Entered into a material agreement, Unregistered sale of equity
May 23
Current report
8-K
Events of May 22
Entered into a material agreement, Unregistered sale of equity
May 20
Current report
8-K
Events of May 15
Delisting notice or listing transfer
May 9
Current report
8-K
Events of May 7
Director or officer change, or executive pay
May 9
Proxy statement
DEFA14A
Proxy statement
May 8
Earnings call
Q1 2024 earnings call
May 8
Current report
8-K
Financial results
May 8
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $388.49M
▲ 28.6%
Net loss $18.7M
Diluted EPS -$0.16
Apr 26
Proxy statement
DEF 14A
Meeting Jun 6, 2024
Proxy statement
Apr 26
Proxy statement
DEFA14A
Proxy statement
Mar 28
Current report
8-K
Events of Mar 22
Entered into a material agreement, Financial results, New debt or off-balance-sheet obligation, Other events
Mar 28
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Revenue $1.27B
▲ 20.7%
Net loss $57.77M
Diluted EPS -$0.63
Mar 12
Current report
8-K
Events of Mar 8
Charter or bylaw amendment, or fiscal year change
Mar 12
Late filing notice
NT 10-K
Late filing notice
Jan 10
Earnings call
Q4 2023 earnings call
Jan 10
Current report
8-K
Events of Jan 9
Financial results, Regulation FD disclosure
2023
Nov 14
Current report
8-K
Events of Nov 8
Entered into a material agreement
Nov 9
Current report
8-K
Other events
Nov 9
Registration statement
S-3
Registration statement
Nov 8
Earnings call
Q3 2023 earnings call
Nov 8
Current report
8-K
Financial results, Regulation FD disclosure
Nov 8
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Revenue $288.35M
▲ 16.1%
Net loss $13.3M
Diluted EPS -$0.12
Aug 7
Earnings call
Q2 2023 earnings call
Aug 7
Current report
8-K
Financial results
Aug 7
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Revenue $329.09M
▲ 22.1%
Net loss $9.82M
Diluted EPS -$0.09
Jul 26
Current report
8-K
Events of Jul 24
Shareholder vote results
Jun 8
Proxy statement
DEF 14A
Meeting Jul 24, 2023
Proxy statement
Jun 8
Proxy statement
DEFA14A
Proxy statement
May 17
Registration statement
S-1/A
Registration statement
May 10
Earnings call
Q1 2023 earnings call
May 10
Current report
8-K
Financial results
May 10
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Revenue $302.08M
▲ 10.4%
Net loss $9.2M
Diluted EPS -$0.22
May 2
Registration statement
S-1
Registration statement
May 1
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2022
Apr 25
Current report
8-K
Other events
Apr 7
Current report
8-K
Events of Apr 6
Entered into a material agreement, Unregistered sale of equity
Mar 31
Current report
8-K
Financial results
Mar 31
Current report
8-K
Events of Mar 30
Entered into a material agreement, Unregistered sale of equity
Mar 31
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Revenue $1.05B
Net loss $270.13M
Diluted EPS -$6.50
Mar 17
Late filing notice
NT 10-K
Late filing notice
Mar 15
Current report
8-K
Events of Mar 14
Financial results, Regulation FD disclosure
Showing 51–100 of 174 documents
Key facts
CIK
1832511
CUSIP
744413204
13F (30d)
27 filings
17 filers
Visit website
Investor relations